Physicians' Academy for Cardiovascular Education

Agenda Topics ▼Video ▼Online-CME News ▼Meeting Reports Slides ▼About

ACC.19 ▼AHA 2019 ▼Diabetes & CVD ▼EAS 2019 ▼ESC 2019 ▼ESC Diabetes guidelines 2019 ▼ESC/EAS Guidelines dyslipidaemias 2019 ▼HFpEF: The essentials to know ▼LDL-c Key Lessons ▼

C-Reactive Protein, Inflammation and Atherosclerosis

Jan. 24, 2016

Share this page with your colleagues and friends:

Continue reading:

4 Things a cardiologist should know about triglycerides

Reducing triglycerides in REDUCE-IT

10' education - Feb. 11, 2020 - Prof. Deepak Bhatt, MD - Online CME

The spectrum of triglyceride-containing lipoproteins

10' education - Feb. 4, 2020 - Jorge Plutzky, MD - Online CME

How can triglycerides increase CV risk?

10' education - Jan. 16, 2020 - Prof. Børge Nordestgaard, MD

5 Things a cardiologist should know about diabetes

Slide Curriculum: Diabetes and cardiology

Slides (curriculum) - July 24, 2018

PACE Special: 5 Things a cardiologist should know about diabetes

Download - Download your free copy

Hypoglycemia in cardiovascular medicine: why worry?

10' education - Mar. 7, 2018 - Prof Guntram Schernthaner - Vienna, Austria - Online CME

ACS

No association between HDL particle concentration and MACE after ACS

Literature - Feb. 10, 2020 - Am Heart J 2019

ACS patients show less dense, calcified plaque than ACS-free controls on clinically indicated CCTA

Literature - Jan. 29, 2020 - Van Rosendael AR et al., - JAMA Cardiol. 2020

Associations of outpatient use of P2Y12 inhibitors with MACE in ACS patients after PCI

Literature - Jan. 28, 2020 - Turgeon RD et al., - JAMA Intern Med. 2020.

Atherosclerosis

EAS consensus statement on key biological mechanisms of LDL-c leading to ASCVD

News - Feb. 27, 2020

Translating ESC/EAS Dyslipidemia Guidelines to clinical practice

10' education - Feb. 18, 2020 - Prof. Kausik Ray, MD

ACS patients show less dense, calcified plaque than ACS-free controls on clinically indicated CCTA

Literature - Jan. 29, 2020 - Van Rosendael AR et al., - JAMA Cardiol. 2020

Atrial fibrillation

SGLT2i reduces atrial fibrillation and atrial flutter in T2DM

Literature - Feb. 17, 2020 - Zelniker TA et al. - Circulation 2020

Less AF recurrence with combination of catheter ablation and renal denervation

Literature - Jan. 28, 2020 - Steinberg JS, et al. - JAMA. 2020

Previously unknown AF prevalent, but AF burden low in at-risk elderly persons with implanted loop recorder

Literature - Dec. 9, 2019 - Diederichsen SZ et al., - J Am Coll Cardiol. 2019

BET Inhibition

Effect of BET inhibition on CV outcomes in ACS and diabetes patients

10' education - Dec. 9, 2019 - Prof. Kausik Ray, MD

Primary endpoint not met for BET inhibitor in phase 3 trial

News - Sep. 30, 2019

BET inhibition, an epigenetic pathway: How could BET inhibition modulate atherothrombotic risk?

10' education - Sep. 30, 2019 - Prof. Wouter Jukema

CV Inflammation

Nordic diet, similar to Mediterranean diet, may also have anti-inflammatory effects

News - Feb. 4, 2020

Pre-PCI P2Y12 inhibitor administration and stent-induced endothelial dysfunction and inflammation in ACS

Literature - Jan. 8, 2020 - Schnorbus B et al., - Eur Heart J. 2020

The burden of residual CV risk in the statin era

5' education - Jan. 6, 2020 - Erin Bohula, MD

CVRM

The growing global challenge of CV risk

5' education - Jan. 15, 2020 - Thomas Gaziano, MD

Persons with NAFLD are not automatically at high risk of acute MI or stroke

Literature - Nov. 4, 2019 - Alexander M et al, - BMJ 2019

Not only weight loss, but also maintaining a lower weight is important for a good CV risk profile

Literature - Oct. 14, 2019 - Berger SE et al., - J Am Heart Assoc. 2019

Diabetes

PCSK9 inhibitor reduces atherogenic lipids in T2DM patients with mixed dyslipidemia

Literature - Feb. 27, 2020 - Colhoun HM, et al. - Cardiovasc Diabetol 2020

SGLT2i reduces atrial fibrillation and atrial flutter in T2DM

Literature - Feb. 17, 2020 - Zelniker TA et al. - Circulation 2020

Baseline HbA1c levels associated with CV outcomes in high risk T2DM patients

Literature - Feb. 10, 2020 - Menon V et al., - J Am Heart Assoc. 2020.

Epigenetics in CVD

Effect of BET inhibition on CV outcomes in ACS and diabetes patients

10' education - Dec. 9, 2019 - Prof. Kausik Ray, MD

BET inhibitor therapy did not meet primary endpoint of reducing MACE in post-ACS patients with T2DM

News - Nov. 17, 2019

Clinical update on BET inhibition: The patient profile that may benefit from BET inhibition

10' education - Aug. 31, 2019 - Prof. Kausik Ray, MD

ESC Diabetes guidelines 2019

Slides: 2019 ESC guidelines on diabetes, pre-diabetes and cardiovascular diseases - Expert insights and rationale

Slides (presentation) - Oct. 7, 2019 - Prof Francesco Cosentino, MD, Stockholm, Sweden - CME symposium held during ESC 2019

The 2019 ESC/EASD diabetes guidelines: a major paradigm shift in the management of T2DM

10' education - Sep. 30, 2019 - Paris, France - Prof. Francesco Cosentino, MD

New ESC/EASD Guidelines on diabetes no longer regard metformin as first-line therapy

News - Sep. 3, 2019

ESC/EAS Guidelines dyslipidaemias 2019

LDL-c targets in the ESC/EAS dyslipidaemia guidelines in a nutshell

10' education - Oct. 4, 2019 - Prof. Brian Ference, MD

Slides: LDL-c targets in the ESC/EAS dyslipidaemia guidelines in a nutshell

Slides (presentation) - Sep. 9, 2019 - ESC Paris, France - Prof. Brian A. Ference, M.D, University of Cambridge, United Kingdom - CME symposium held during ESC 2019

Rationale for the lower LDL-c targets in the 2019 ESC/EAS Dyslipidemia Guidelines

5' education - Sep. 9, 2019 - Paris, France - Prof. François Mach

Expert Meeting GLP-1, CVD & T2DM

Translation of novel approaches in CVD & diabetes to clinical practice

10' education - Mar. 22, 2018 - John Deanfield, Francesco Cosentino, Filip Knop - Online CME

Novel diabetes drugs in clinical management: Extending the opportunities

10' education - June 5, 2018 - Stefano Taddei, Cees Tack, Massimo Volpe - Online CME

Clinical trials in diabetes and CVD: What did we learn?

10' education - Mar. 22, 2018 - Filippo Crea, Angelyn Bethel, Eduard Montanya - Online CME

Familial Hypercholesterolemia

Monogenic FH associated with higher CVD risk compared with polygenic hypercholesterolemia

Literature - Feb. 20, 2020 - Trinder M et al., - JAMA Cardiol. 2020.

Sustained efficacy and safety of PCSK9 antibody in HoFH and severe HeFH

Literature - Feb. 12, 2020 - Santos RD et al., - J Am Coll Cardiol. 2020

New screening tool uses machine learning to identify individuals with probable FH in large datasets

Literature - Dec. 10, 2019 - Myers KD et al., - Lancet Digit Health. 2019

GLP-1 RA & CVD

Impacting progression and outcomes of DKD: Translating novel insights with GLP-1RA to practice

Online-CME - This course consists of 3 lectures.

Subgroup analyses in GLP1-RA trial meta-analysis to understand the varying outcomes seen with different GLP-1RAs

Literature - Oct. 22, 2019 - Kristensen SL et al., - Lancet Diabetes Endocrinol. 2019

Mechanisms of action of GLP-1RAs

10' education - Oct. 21, 2019 - Prof. Filip Knop, MD

Heart Failure

HFpEF: A misunderstood disease in search of a therapy

10' education - Jan. 23, 2020 - Prof. Scott Solomon

Down-titration of diuretics predicts achievement of target dose of ARNI in real-world HFrEF patients

Literature - Jan. 21, 2020 - Pharithi RB et al., - ESC Heart Fail. 2020.

Clinical phenotype-based HFpEF subgroups respond differently to aldosterone antagonist therapy

Literature - Jan. 15, 2020 - Cohen JB et al., - JACC Heart Fail. 2020

HFpEF: The essentials to know

HFpEF: Current and future clinical approaches to manage HFpEF

10' education - Aug. 27, 2018 - Burkert Pieske, MD - Berlin, Germany - Online CME

Slides: HFpEF: What are the most likely pathophysiological mechanisms involved in the disease

Slides (presentation) - Aug. 27, 2018 - Carolyn Lam, MD - Singapore

HFpEF: How to diagnose

10' education - Aug. 27, 2018 - Barry Borlaug - Rochester, MN, USA - Online CME

Hypertension

Faster rates of BP elevation with aging in women vs. men

Literature - Jan. 27, 2020 - Ji H, et al. - JAMA Cardiol. 2020

Thiazide or thiazide-like diuretics superior to ACEi as initial monotherapy in hypertension

Literature - Nov. 12, 2019 - Suchard MA, et al. - The Lancet 2019

Hypertension medication ingestion at bedtime improves asleep ABP and reduces CVD risk

Literature - Oct. 31, 2019 - Hermida RC et al., - Eur Heart J 2019

Inflammation Expert Opinions

Ultime notizie sulla terapia: Un farmaco anti-infiammatorio riduce eventi cardiovascolari maggiori

5' education - Aug. 27, 2017 - ESC 2017, Barcelona, Spain

Breakthrough therapy: Anti-inflammatory drug can affect important CV outcomes

5' education - Aug. 27, 2017 - ESC 2017, Barcelona, Spain

Clinical implications of inhibiting inflammation as risk factor for progression of CVD

5' education - Aug. 27, 2017

Invest in your arteries

Estimating CV risk and treatment benefit

10' education - June 12, 2018 - Prof. Frank Visseren - Utrecht, The Netherlands - Online CME

Importance of hypertension in CVD prevention

10' education - June 12, 2018 - Prof. Richard Hobbs - Oxford, UK - Online CME

The role of lipids in CVD prevention: Lessons learned about statins

10' education - June 6, 2018 - Prof. Kees Hovingh - Amsterdam, The Netherlands - Online CME

Lipids

PCSK9 inhibitor reduces atherogenic lipids in T2DM patients with mixed dyslipidemia

Literature - Feb. 27, 2020 - Colhoun HM, et al. - Cardiovasc Diabetol 2020

Lipids beyond LDL-c: HDL-c and triglycerides

5' education - Feb. 25, 2020 - Prof. Peter Libby, MD

Patient-reported cognition at the end of a PCSK9 antibody trial

5' education - Nov. 17, 2019 - Baris Gencer, MD

Lp(a)

High level of ApoCIII-Lp(a) complexes together with high Lp(a) or OxPL predicts rapid progression of aortic stenosis

Literature - Feb. 26, 2020 - Capoulade R et al. - Heart 2020

Assessing residual lipid risk with advanced testing

5' education - Feb. 17, 2020 - Samia Mora, MD

Rationale of new recommendations in ESC/EAS Guidelines for Dyslipidemia

10' education - Dec. 19, 2019 - Prof. Ulf Landmesser, MD

PCSK9

PCSK9 inhibitor reduces atherogenic lipids in T2DM patients with mixed dyslipidemia

Literature - Feb. 27, 2020 - Colhoun HM, et al. - Cardiovasc Diabetol 2020

Patient-reported cognition at the end of a PCSK9 antibody trial

5' education - Nov. 17, 2019 - Baris Gencer, MD

Translating ESC/EAS Dyslipidemia Guidelines to clinical practice

10' education - Feb. 18, 2020 - Prof. Kausik Ray, MD

Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension: Key questions addressed

Online-CME - This course consists of 3 separate lectures

Why cardiologists should be more interested in PAH

3' education - Mar. 9, 2018 - VBWG at ACC, Orlando, FL, USA - Prof. Mardi Gomberg-Maitland, Falls Church, VA, USA - Online CME

Novel insights in the management and prognosis of pulmonary hypertension

5' education - Aug. 29, 2017 - ESC 2017, Barcelona, Spain - Prof Nazzareno Galiè - Bologna, Italy

Stroke

P2Y12 inhibitor plus aspirin reduces risk of primary endpoint after acute ischemic stroke or TIA

News - Jan. 28, 2020

Prestroke smoking status affects functional outcomes after acute ischemic stroke

Literature - Jan. 28, 2020 - Matsuo R et al., - Stroke. 2020

LDL-c target of <70 vs. 100 mg/mL after stroke lowers risk of CV events

News - Nov. 25, 2019

© 2006 - 2020 pace-cme.org - About